MT-1 (Melanotan I) — Mechanism, Research & Limitations

This article is for informational and educational purposes only and does not constitute medical advice. MT-1 is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for general human or veterinary use.

Wholesale Peps is not affiliated with, endorsed by, or in any way connected to Clinuvel Pharmaceuticals Ltd or the Scenesse® brand. This research review is compiled from publicly available peer-reviewed literature for educational purposes only.

Research Summary

MT-1 (Melanotan I), formally designated [Nle⁴,D-Phe⁷]-α-MSH and assigned the International Nonproprietary Name (INN) afamelanotide, is a synthetic linear tridecapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) developed at the University of Arizona by Mac Hadley, Victor Hruby, and colleagues as part of the same melanocortin analogue programme that later produced MT-2 [1]. MT-1 retains the full 13-amino acid length of native α-MSH but incorporates two key substitutions — norleucine (Nle) at position 4 replacing oxidation-prone methionine, and D-phenylalanine (D-Phe) at position 7 replacing L-Phe — that markedly increase potency, metabolic stability, and receptor binding affinity relative to the native peptide. MT-1 is more selective for MC1R over MC4R than its cyclic derivative MT-2, producing a pharmacological profile weighted toward peripheral pigmentation effects with reduced CNS activity. The pharmaceutical development of MT-1 culminated in afamelanotide (Scenesse®), an implant formulation developed by Clinuvel Pharmaceuticals that received European Medicines Agency (EMA) approval in 2014 and U.S. FDA approval in 2019 for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP) [3]. MT-1 itself, as research-grade lyophilized material, is a distinct preparation from the approved pharmaceutical formulation and is not approved for human use outside of that specific indication.

1. Background

1.1 Alpha-MSH and the Melanocortin System

Alpha-melanocyte-stimulating hormone (α-MSH) is a 13-amino acid peptide hormone derived from post-translational processing of pro-opiomelanocortin (POMC). It is produced by corticotroph cells of the pituitary, by neurons in the arcuate nucleus of the hypothalamus, and by melanocytes and keratinocytes in the skin. α-MSH acts through a family of G-protein-coupled receptors, the melanocortin receptors (MC1R–MC5R), to regulate melanin synthesis, energy homeostasis, inflammation, and sexual function [2].

The pharmacologically active core of α-MSH resides in the central tetrapeptide His-Phe-Arg-Trp (residues 6–9), which constitutes the minimum sequence required for melanocortin receptor binding and activation. Native α-MSH has a short plasma half-life driven by rapid proteolytic degradation at both termini and at the Met residue at position 4, which is susceptible to oxidation. These stability limitations motivated the synthesis of analogues incorporating protective modifications while retaining the pharmacophore.

1.2 Melanocortin Receptor Subtypes

Five melanocortin receptor subtypes (MC1R–MC5R) have been characterised, each with distinct tissue distributions and physiological roles [2]:

MC1R — Expressed predominantly on epidermal melanocytes and melanoma cells; governs eumelanin vs. phaeomelanin switching and is the primary peripheral target of MT-1. Also expressed on immune cells and in the CNS.
MC2R — The ACTH receptor, restricted to the adrenal cortex; not meaningfully activated by MT-1.
MC3R — Expressed in hypothalamic and peripheral metabolic tissues; role in energy sensing. MT-1 shows lower affinity at MC3R than MT-2.
MC4R — Widely expressed in the hypothalamus and limbic circuits; mediates appetite suppression, sexual arousal, and autonomic function. MT-1’s lower MC4R activity relative to MT-2 is a key distinguishing pharmacological feature.
MC5R — Expressed in exocrine glands and skeletal muscle; role not fully characterised.

1.3 Development of MT-1

The University of Arizona melanocortin programme began systematically modifying α-MSH in the 1960s and 1970s, with early work demonstrating that synthetic melanocortin fragments could stimulate pigmentation in amphibian and mammalian models. The first goal was to identify a stabilised, potent linear analogue of the full α-MSH sequence. MT-1, incorporating the Nle⁴ and D-Phe⁷ substitutions into the complete 13-amino acid α-MSH framework, emerged from this effort as a compound substantially more potent and metabolically stable than native α-MSH while remaining a linear, non-cyclic peptide.

Levine and colleagues administered subcutaneous MT-1 to healthy volunteers in an early human study reported in 1991, demonstrating dose-dependent skin tanning without UV exposure and establishing proof of concept for synthetic melanocortin peptides as pigmentation agents in humans [1]. Subsequent pharmaceutical development by Clinuvel Pharmaceuticals refined MT-1 into afamelanotide — the same molecular entity in a controlled-release subcutaneous implant formulation — and conducted the clinical trials that led to regulatory approval for EPP. MT-2, the cyclic derivative, was developed in parallel and subsequently characterised as a shorter, more potent, but less MC1R-selective analogue.

2. Molecular Structure

MT-1 has the sequence Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂, corresponding to the full 13-amino acid α-MSH sequence with two substitutions: Met→Nle at position 4 and L-Phe→D-Phe at position 7. The compound carries an N-terminal acetyl group (Ac-) and a C-terminal amide (-NH₂), both contributing to metabolic stability. It is a linear tridecapeptide with a molecular weight of approximately 1,647 Da.

Ac–

Ser

Serine

–

Tyr

Tyrosine

–

Ser

Serine

–

Nle

Nle*

–

Glu

–

His

–

D-Phe

D-Phe*

–

Arg

–

Trp

–

Gly

–

Lys

–

Pro

–

Val

–NH₂

Modified (Nle, D-Phe)

Acidic (Glu)

Basic (His, Arg, Lys)

Aromatic (Tyr, Trp)

* Nle (position 4): norleucine replaces Met — eliminates oxidative liability, retains hydrophobic character. | * D-Phe (position 7): D-stereoisomer of phenylalanine — induces β-turn in pharmacophore, greatly increases MC1R affinity and proteolytic stability. | Ac– = N-terminal acetyl | –NH₂ = C-terminal amide. Linear (non-cyclic) backbone.

Table 1 — Key Structural Modifications in MT-1 Relative to Native α-MSH
Position	Native α-MSH	MT-1	Rationale
Position 4	Met (oxidation-prone)	Nle (Norleucine)	Eliminates sulfur oxidation; retains hydrophobicity and side-chain length
Position 7	L-Phe	D-Phe	Induces pharmacophore β-turn; greatly increases MC1R affinity and proteolytic resistance
N-terminus	Free amine (as in native α-MSH)	Acetyl group (Ac-)	Protection from aminopeptidases; reduced charge
C-terminus	Free carboxyl	Amide (-NH₂)	Protection from carboxypeptidases; improved metabolic stability
Backbone topology	Linear	Linear (13 residues retained)	Distinguishes MT-1 from MT-2 (cyclic heptapeptide); longer sequence, greater MC1R selectivity

Table 2 — MT-1 Compound Profile
Property	Detail
Full sequence	Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂
INN designation	Afamelanotide (pharmaceutical form)
Length	13 amino acids (linear tridecapeptide)
Molecular weight	~1,647 Da
Structural class	Linear; N-acetylated; C-amidated
Primary MCR target	MC1R (more selective than MT-2; residual MC3R, MC4R activity)
Origin	University of Arizona (Hadley/Hruby group)
Related approved compound	Afamelanotide (Scenesse®) — EMA approved 2014, FDA approved 2019 for EPP

MT-1 vs MT-2: Key Differences

MT-1 and MT-2 both originate from the same University of Arizona melanocortin programme but differ substantially in structure and pharmacological profile. The comparison below is relevant for researchers choosing between them or interpreting published literature that distinguishes the two compounds.

Table 3 — MT-1 vs MT-2 Structural and Pharmacological Comparison
Feature	MT-1 (Melanotan I)	MT-2 (Melanotan II)
Backbone topology	Linear	Cyclic (lactam bridge)
Length	13 amino acids	7 amino acids
Molecular weight	~1,647 Da	~1,025 Da
MC1R selectivity	Higher (primary target)	Lower (non-selective)
MC4R activity	Lower (residual)	Higher (prominent)
CNS effects	Lower at pigmenting doses	Higher (appetite, libido, nausea)
FDA-approved form	Afamelanotide (Scenesse®) for EPP — 2019	None
INN designation	Afamelanotide	None assigned

3. Mechanism of Action

MT-1 acts primarily as an agonist at MC1R, with the linear 13-residue backbone conferring greater MC1R selectivity relative to the cyclic heptapeptide MT-2. Its physiological effects are dominated by peripheral melanocyte activation and the downstream eumelanin synthesis cascade, with substantially less CNS activity than observed with MT-2 at comparable doses.

Primary Target

MC1R Agonism — Eumelanin Induction

MC1R activation on epidermal melanocytes couples through Gαs to adenylyl cyclase, elevating intracellular cAMP and activating PKA. This phosphorylates CREB and induces transcription of MITF, the master regulator of melanogenesis, which drives expression of tyrosinase, TYRP1, and TYRP2. The net effect is a shift from phaeomelanin (red/yellow) to eumelanin (brown/black) production, resulting in UV-independent skin darkening [1,2].

Established

Photoprotective Signaling via Eumelanin

Eumelanin is a broad-spectrum UV absorber and free radical scavenger. MC1R-driven eumelanin deposition in the epidermis provides a photoprotective function by reducing UV-induced DNA damage in keratinocytes and melanocytes. In erythropoietic protoporphyria, where patients accumulate photosensitising protoporphyrin IX and experience severe phototoxic reactions on UV exposure, pre-emptive MC1R-mediated eumelanin induction has been studied as a strategy to increase light tolerance [3].

Established / Class

Anti-Inflammatory MC1R Signaling

MC1R is expressed not only on melanocytes but also on monocytes, macrophages, and dendritic cells, where its activation modulates inflammatory cytokine production. MC1R agonism has been associated with suppression of NF-κB-dependent pro-inflammatory signalling and reduction of reactive oxygen species in immune cell populations. This peripheral anti-inflammatory component is not the primary studied effect of MT-1 in published research but may contribute to observed responses.

Residual / Lower Activity

MC4R and MC3R Activity

MT-1’s linear 13-residue structure confers greater MC1R selectivity than MT-2’s cyclic heptapeptide scaffold, but MT-1 is not a fully selective MC1R agonist. At higher concentrations, residual activity at MC3R and MC4R can be detected in receptor binding assays. In the early human studies, adverse effects including nausea — likely mediated by MC3R/MC4R in brainstem circuits — were reported at doses sufficient to produce pigmentation, suggesting some off-target MCR engagement [1,4].

4. Key Research Findings

Evidence Context: MT-1 has an unusual evidence profile among research peptides: it has been evaluated in both early academic human studies and in full Phase 3 regulatory trials, but exclusively in its pharmaceutical afamelanotide formulation for the specific indication of EPP. Evidence from afamelanotide trials reflects a controlled implant formulation at a specific dose and cannot be directly extrapolated to research-grade lyophilized MT-1 preparations.

4.1 MC1R Pharmacology and Structure-Activity Relationship

The receptor binding profile and structure-activity relationships of MT-1 were characterised extensively through the University of Arizona programme and subsequent academic work. The Nle⁴,D-Phe⁷ substitutions increase MC1R binding affinity relative to native α-MSH, with D-Phe⁷ being the dominant driver of potency enhancement through its induction of a β-turn conformation in the His-D-Phe-Arg-Trp pharmacophore [4]. Comparative receptor binding studies established that MT-1 has higher MC1R selectivity than MT-2 (the cyclic derivative), a property attributed to the extended linear backbone offering additional contacts with the MC1R extracellular domain that are not present in the shorter cyclic structure.

4.2 Pigmentation and Skin Tanning

Levine, Dorr, Hadley, Hruby, and colleagues (1991) reported subcutaneous administration of MT-1 to healthy volunteers in a dose-escalation study, demonstrating dose-dependent skin darkening consistent with MC1R-mediated eumelanin induction [1]. Tanning was observed without concurrent UV exposure, confirming the UV-independent mechanism of MC1R-driven pigmentation. The study also documented the adverse effect profile at pigmenting doses, which included nausea, flushing, and spontaneous erections — the latter consistent with residual MC4R activity. This early human work established the pharmacodynamic proof of concept for MT-1 in humans and provided the foundation for subsequent pharmaceutical development.

4.3 Erythropoietic Protoporphyria (EPP) Research

Erythropoietic protoporphyria is a rare inherited disorder of haem synthesis characterised by accumulation of protoporphyrin IX in erythrocytes, plasma, and skin, leading to severe phototoxic pain reactions upon exposure to visible and near-UV light. Patients typically experience incapacitating burning pain within minutes of sun exposure, substantially restricting quality of life and outdoor activity.

Langendonk and colleagues (2015) published results from a Phase 3 randomised, double-blind, placebo-controlled trial of afamelanotide (the pharmaceutical MT-1 implant, 16 mg) in 94 patients with EPP [3]. Afamelanotide-treated patients showed a statistically significant increase in the time they could spend in direct sunlight without experiencing phototoxic pain, along with improvements in quality of life measures, compared with placebo. The most common adverse effects were implant-site reactions, nausea, and skin darkening (as an expected pharmacodynamic effect). This trial served as a key component of the regulatory submission supporting EMA approval in 2014 and contributed to subsequent FDA approval in 2019.

4.4 Relationship to Afamelanotide (Scenesse®)

Afamelanotide is the international non-proprietary name (INN) assigned to the pharmaceutical form of MT-1, formulated as a controlled-release subcutaneous implant by Clinuvel Pharmaceuticals (brand name Scenesse®). The approved indication is prevention of phototoxicity in adults with EPP, administered as a 16 mg biodegradable implant every two months during the period of greatest sun exposure. The EMA approved afamelanotide in 2014 and the FDA in 2019, making it one of a small number of peptide melanocortin agonists to receive regulatory approval [3,4].

The existence of an approved pharmaceutical form establishes proof of concept for MC1R agonism as a therapeutic mechanism and confirms that the pharmacological target and general activity profile of the molecule are clinically tractable. However, afamelanotide and research-grade MT-1 are distinct preparations: the approved implant uses a specific biodegradable polymer matrix providing controlled release kinetics, is manufactured under pharmaceutical GMP standards, and is used at a defined dose for a specific patient population. Research-grade lyophilized MT-1 is a different preparation with different pharmacokinetic properties and has not been evaluated in the regulatory context.

Wholesale Peps is not affiliated with, endorsed by, or associated with Clinuvel Pharmaceuticals Ltd or the Scenesse® brand.

Fig. 1 — MT-1 vs MT-2 Melanocortin Receptor Selectivity Profile

Relative activity values are qualitative estimates based on comparative receptor binding literature and do not represent quantitative K_i values. MT-1 demonstrates clear MC1R predominance (92% relative activity) with low MC4R engagement (18%), in contrast to MT-2 which shows more balanced activity across MC1R (72%) and MC4R (78%). MC2R is not meaningfully activated by either compound. Consult primary pharmacology literature for quantitative binding data.

5. Evidence Status

Table 3 — MT-1 Evidence Hierarchy by Claim
Claim / Effect	Supporting Evidence	Evidence Level
MC1R binding and activation; structural basis for potency	Extensive in vitro receptor pharmacology; D-Phe⁷ potency enhancement well-characterised in SAR studies	Strong
Skin pigmentation in humans (afamelanotide)	Early human dose-escalation study (Levine et al. 1991); confirmed pharmacodynamic effect in EPP trials as an expected finding	Strong
EPP phototoxicity prevention (afamelanotide formulation)	Phase 3 randomised controlled trial (Langendonk et al. 2015); EMA and FDA approved indication	Strong
Greater MC1R selectivity vs MT-2	Established from receptor binding assay comparisons; consistent with linear vs. cyclic structural differences	Moderate
Anti-inflammatory effects via MC1R	In vitro data on MC1R-expressing immune cells; not a primary studied endpoint in clinical EPP research	Limited
Safety and efficacy for indications beyond EPP	No Phase 2/3 data outside EPP indication; early human tanning study not a controlled safety trial	Limited

6. Limitations of Current Research

Research-Grade MT-1 ≠ Approved Afamelanotide The regulatory approval of afamelanotide (Scenesse®) for EPP applies specifically to the controlled-release implant formulation at the approved dose and patient population. Research-grade lyophilized MT-1 is the same molecular entity but an entirely different preparation with different pharmacokinetics, no controlled release profile, and no regulatory assessment for human use outside the approved indication. Clinical findings from afamelanotide EPP trials cannot be assumed to extend to other formulations or uses.

EPP Approval Does Not Extend to Cosmetic or General Pigmentation Use The approved indication for afamelanotide is prevention of phototoxic reactions in EPP, a rare and severe disease condition. The approval was granted for a specific benefit-risk assessment in a patient population with serious unmet medical need. This approval does not confer regulatory sanction for MT-1 use as a tanning agent or for general photoprotection in healthy individuals, uses for which no comparable Phase 3 trials have been conducted and which carry a different benefit-risk profile.

Residual MC4R Activity and Off-Target Effects MT-1 is not a fully selective MC1R agonist. At doses sufficient to produce pigmentation in early human studies, nausea, flushing, and spontaneous erections were reported, consistent with residual MC4R and potentially MC3R engagement. The dose required to achieve peripheral MC1R-mediated pigmentation overlaps with doses producing CNS off-target effects, limiting the therapeutic window for applications where selective pigmentation without CNS activity is the goal.

Theoretical Concerns Regarding Melanocyte Stimulation Repeated or chronic MC1R stimulation in melanocytes has prompted theoretical questions about effects on naevi (moles) and potential interactions with melanoma biology, given that MC1R signalling is active in melanocytic cells and plays a role in the UV tanning response. Whether exogenous MC1R agonism influences naevus development or melanoma risk has not been evaluated in adequately powered long-term controlled studies. The EPP trials followed patients over months-to-years and did not identify excess melanoma incidence, but these trials were not powered or designed to evaluate this endpoint.

Limited Controlled Data on Long-Term Safety Beyond EPP Trials The controlled human safety data for MT-1 derive primarily from the EPP clinical programme, which evaluated a specific patient population at a fixed implant dose. Pharmacokinetics, dose-response relationships, and safety profiles for research-grade MT-1 administered by other routes or at other doses are not established from controlled published evidence. Long-term cardiovascular, endocrine, and dermatological safety beyond the EPP trial follow-up periods is not characterised from independent research.

Research-Grade Compound Status MT-1 is available from Wholesale Peps as a lyophilized research-grade peptide for in vitro laboratory use only. The physical, chemical, and microbiological properties of research-grade material are characterised for in vitro research purposes and are not equivalent to those required for pharmaceutical-grade compounds intended for administration to humans or animals.

⚠ Research and Informational Use Only. All content on this page is for informational and educational purposes and is intended for qualified research professionals. Nothing on this page constitutes medical advice, diagnosis, or treatment guidance. MT-1 is supplied by Wholesale Peps as lyophilized powder for in vitro laboratory research only and is not approved by the FDA for general human or veterinary use. Read full disclaimer →

References

Levine N, Sheftel SN, Eytan T, Dorr RT, Hadley ME, Weinrach JC, Ertl GA, Toth K, McGee DL, Hruby VJ. “Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin.” JAMA. 1991;266(19):2730–2736. doi:10.1001/jama.1991.03470190079033
Cone RD. “Anatomy and regulation of the central melanocortin system.” Nature Neuroscience. 2005;8(5):571–578. doi:10.1038/nn1455
Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FP, Sijbrands EJ, De Rooij FW, Lebwohl M, Naik H, Goding CR, Wilson JH, Desnick RJ. “Afamelanotide for erythropoietic protoporphyria.” New England Journal of Medicine. 2015;373(1):48–59. doi:10.1056/NEJMoa1411481
Hadley ME, Dorr RT. “Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.” Peptides. 2006;27(4):921–930. doi:10.1016/j.peptides.2005.01.029
Wikberg JE, Muceniece R, Mandrika I, Prusis P, Lindblom J, Post C, Skottner A. “New aspects on the melanocortins and their receptors.” Pharmacological Research. 2000;42(5):393–420. doi:10.1006/phrs.2000.0701